Aquestive Therapeutics, Inc.
Aquestive Therapeutics is a U.S.-based pharmaceutical company focused on developing and manufacturing medicines that use proprietary delivery technologies to make complex drugs easier to administer. Its core platform, PharmFilm®, supports oral film and other non-invasive dosage forms, while its pipeline includes Anaphylm™, a late-stage epinephrine prodrug candidate for severe allergic reactions, and the broader AdrenaVerse™ platform. The company also earns revenue from four licensed commercialized products that are marketed by partners in the U.S. and internationally, with Aquestive serving as the exclusive manufacturer. In addition to internal development, it collaborates with other pharmaceutical companies to bring new molecules to market using its delivery science and manufacturing capabilities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLate-stage and pipeline medicines developed for Aquestive's own commercialization or partnering, including Anaphylm and AdrenaVerse.
Contract manufacturing of licensed products that partners commercialize in the U.S. and globally.
Royalties and licensing income from intellectual property and partnered products.
Development services and collaboration fees earned under pharmaceutical partner agreements.
Self-commercialized products such as Libervant, where applicable, though access has been disrupted by litigation and FDA action.
Products
Reported · share of revenue- Manufacture and Supply Revenue89.3 %
- License and Royalty Revenue7.8 %
- Co Development and Research Fees2.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Aquestive sells primarily to pharmaceutical partners rather than directly to end consumers, which makes its business model heavily B2B and collaboration-driven. Its manufacturing customers are licensees that rely on Aquestive to produce approved products to agreed specifications, while its licensing customers pay for access to proprietary delivery technology and intellectual property. The company also serves development partners that use its PharmFilm platform and related capabilities to advance new molecules through co-development arrangements. For its proprietary products, the end users are patients and prescribers, but commercialization depends on regulatory approval, market access, and distribution partners.
Buy manufactured doses of licensed products from Aquestive because the company is the exclusive manufacturer and they need reliable supply for commercialization.
Use Aquestive's delivery technologies and development capabilities to advance new molecules and formulations through co-development agreements.
Pay license and royalty fees tied to commercialized products that use Aquestive's intellectual property.
Use proprietary products such as Libervant and, if approved, Anaphylm, because the company aims to offer less invasive alternatives to standard care.
Strategy
Aquestive's strategy centers on advancing Anaphylm and the AdrenaVerse platform while preserving optionality through partnering and outlicensing. The company is also focused on supporting its existing licensed-product manufacturing base, which provides commercial revenue and helps fund development activities. Management has signaled that liquidity is a major constraint, so cost control, external financing, and potential strategic transactions are part of the operating plan. The company is trying to balance near-term cash preservation with continued investment in late-stage development programs that could create a larger proprietary commercial opportunity.
Anaphylm is the company's most important late-stage proprietary asset and could materially change the business mix if approved.
The company expects continued losses and negative cash flow, so funding is required to sustain development and debt service.
Outlicensing can reduce commercialization burden and create milestone or royalty income while limiting cash burn.
PharmFilm and related technologies are the company's core differentiation and can support future collaborations.
Geography
Q1/2026Aquestive is headquartered in Warren, New Jersey, with manufacturing operations in Portage, Indiana, and its primary research laboratory also based in New Jersey. The company markets and supplies products through licensees in the United States and around the world, so its commercial footprint is global even though its own operating base is U.S.-centric. Regulatory oversight spans multiple jurisdictions, including the FDA in the U.S. and inspections by TGA, DEA, ANVISA, and EMA, which matters because manufacturing and quality compliance are central to its supply business. The company does not disclose a country-level revenue split in the provided excerpts, so the geographic profile is best understood through its U.S. operating base and international partner commercialization.
Share of the revenue the company reports by geography.
Risks
Aquestive faces substantial development and regulatory risk because its lead proprietary programs depend on FDA approval and the company has already received a complete response letter for Anaphylm. Its business is also exposed to clinical execution risk because it relies heavily on third-party CROs, investigators, and consultants to run trials and generate the data needed for approval. Commercial risk is elevated because the company depends on a small number of licensed products and on partner commercialization decisions, while litigation or loss of market access can quickly disrupt revenue, as seen with Libervant. More broadly, the company operates in a highly competitive pharmaceutical market with strong intellectual property defense, pricing pressure, reimbursement uncertainty, and ongoing need for capital, all of which can affect both growth and survival.
- Liquidity shortfall and refinancing riskImpact: CriticalLikelihood: High
The company expects continued losses and needs capital to fund operations, development, and debt service.
Exposure: Operating runway and 13.5% Notes
- FDA regulatory setbacks for AnaphylmImpact: HighLikelihood: High
The lead proprietary program depends on resolving FDA concerns and obtaining approval, and a delay or rejection would materially impair growth prospects.
Exposure: Anaphylm and the broader epinephrine prodrug strategy
- Commercial concentration in a limited product setImpact: HighLikelihood: High
Revenue depends on a small number of licensed products and proprietary launches, making the business vulnerable to single-product disruption.
Exposure - Clinical trial execution dependence on CROsImpact: HighLikelihood: Medium
Delays, data quality issues, or vendor failures could slow or invalidate development programs.
Exposure: Preclinical and clinical pipeline
- Intellectual property and litigation exposureImpact: MediumLikelihood: Medium
The company relies on proprietary delivery technologies and may face disputes over patents, trade secrets, or commercialization rights.
Exposure: PharmFilm and product pipeline
Accounting
Judgemental itemsManufacturing, licensing, royalties, co-development fees, and proprietary product sales have different recognition triggers and can create quarter-to-quarter volatility.
Impact: Affects reported revenue mix and comparability
Returns, prompt-pay discounts, rebates, and co-pay support require estimates that can later be adjusted to actuals.
Impact: Affects net revenue and accrued liabilities
The KYNMOBI arrangement is treated as debt financing, with interest expense based on expected royalty payments.
Impact: Affects leverage presentation and interest expense
Pipeline programs such as Anaphylm and AdrenaVerse depend on approval and commercialization assumptions that may require impairment or write-down analysis.
Impact: Affects asset carrying values and loss recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Exicure, Inc
XCUR · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026